Nebulized mRNA formulations for pulmonary delivery

Technology
Conceptual
University
Scouted & summarized by Halo AI

University of Pennsylvania researchers, as part of a collaborative study, have developed a combinatorial approach to improve the stability and efficacy of nebulized mRNA lipid nanoparticles (LNPs). By optimizing buffer conditions, using stability-enhancing excipients, and identifying high-performance ionizable lipids like IR-117-17, the team achieved significant improvements in pulmonary mRNA delivery over existing methods. This research provides a critical foundation for developing effective inhaled nanotherapies for various lung diseases.

Overview

The University of Pennsylvania, in collaboration with researchers from MIT and other institutions, has developed a combinatorial approach to enhance the stability and delivery efficiency of nebulized mRNA lipid nanoparticles (LNPs) to the lungs. Nebulized delivery is a promising route for treating pulmonary diseases, but traditional LNPs often suffer from stability issues during the nebulization process, such as aggregation and cargo release. This research introduces stabilized LNP formulations and novel ionizable, degradable lipids that significantly improve mRNA delivery compared to existing state-of-the-art technologies.

Technical specifications

The technology utilizes a multifaceted strategy to address the challenges of inhaled mRNA delivery:

  • Formulation Stabilization: LNP charge is increased during the nebulization process by adjusting the buffer conditions.
  • Stability-Enhancing Excipients: A branched polymeric excipient is added to prevent nebulization-induced aggregation.
  • Novel Ionizable Lipids: Through a combinatorial library screening process, two lead lipid candidates, IR-117-17 and IR-19-Py, were identified. These lipids, when combined with the optimized formulation and excipients, demonstrate superior performance in targeting lung and nasal tissues.
  • High-Throughput Screening: The researchers utilized primary air-liquid interface (ALI) lung epithelial cell cultures as a high-throughput, predictive model to evaluate and optimize these formulations, proving more accurate than traditional submerged cell-culture assays.
Technology readiness level

The technology is currently at TRL 3-4 (Conceptual/Lab validation). The research successfully demonstrated proof-of-concept for these formulations in fully differentiated air-liquid interface cell cultures and preclinical in vivo mouse models. While the results show significant performance improvements over existing methods, the technology remains in the research and development phase...

Generated Oct 28, 2026. Please verify key information.

About University of Pennsylvania

The University of Pennsylvania is a private, comprehensive research university with a large, interdisciplinary research enterprise on an urban campus in Philadelphia. For industry, the university combines an integrated academic health system with a research and technology park featuring co‑located labs, pilot and prototyping spaces, and access to shared instrumentation. Dedicated corporate engagement and technology transfer teams streamline sponsored research, IP, and startup formation, with incubator and venture resources to accelerate commercialization. Faculty attract substantial competitive federal funding from agencies such as the National Institutes of Health, National Science Foundation, Department of Energy, and the Department of Defense.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.